Sign in
CompletedPhase 2

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Switzerland3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
272 people enrolled
Started
19 Jul 2018
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rivaroxaban 10 MG Oral Tablet [Xarelto]
Record updated
13 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients with scheduled elective bariatric surgery or redo surgery after bariatric interventions
  • Written informed consent

Who cannot take part

  • Myocardial infarction, transient ischemic attack or stroke within 6 months of study entry
  • Uncontrolled hypertension
  • DVT and/or PE in the patient history

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery.

Read full original descriptionShow less

The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.

All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to detect clinically inapparent thromboses.

In a subgroup of study patients (patients from the University Hospital Inselspital, Bern) PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.

The 2 groups in the trial

  • A: Rivaroxaban short armExisting treatment, for comparison

    7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.

    Treatment: Rivaroxaban 10 MG Oral Tablet [Xarelto]

  • B: Rivaroxaban long armExisting treatment, for comparison

    28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o. Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28

    Treatment: Rivaroxaban 10 MG Oral Tablet [Xarelto]

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Publications
Record updated
13 November 2024